Biotechnology New data supporting the long-term safety of Cimzia (certolizumab pegol), the only Fc-free, PEGylated anti-tumor necrosis factor (TNF), in patients with moderate-to-severe plaque psoriasis, and new efficacy data for patients who show signs of psoriasis-related nail disease and those who had an inadequate early treatment response to Cimzia, were released today. 25 April 2019